Abbott Laboratories stock slips as rate fears weigh on medical device sector

Abbott Laboratories (ISIN US0028241000) stock is trading below its start-of-year levels, with recent market data showing the share at about USD 108.93 and down around 17.1% over the past twelve months as of September 2, 2026, according to an overview of medical device stocks by Stake.

Medical device stocks under pressure

The broader medical device group has been facing valuation pressure as investors react to higher-for-longer interest rate expectations in the United States, a dynamic that is weighing on growth-oriented healthcare names including Abbott Laboratories as of September 2, 2026, according to sector commentary compiled by Stake.

Within that peer set, Abbott is cited with a share price of USD 108.93, a daily move of negative 1.3 percent and a market capitalization of USD 190.97 billion as of September 2, 2026, highlighting its role as a large-cap healthcare equipment player rather than a small speculative biotech, based on data from Stake.

Stock performance over the past year

For retail investors, the twelve-month performance provides important context: Abbott Laboratories stock started the last year at USD 131.46 and ended the period at USD 108.93, a decline of 17.1 percent according to the same Stake overview, showing that the share has lagged a number of broader indices and that the re-rating has already been substantial as of September 2, 2026.

This performance means that the current price of USD 108.93 is materially below the prior level at USD 131.46, a gap of USD 22.53 per share, underscoring how the market has adjusted expectations for future growth and profitability in the medical device segment, according to the figures reported by Stake.

Diagnostics and precision medicine footprint

Beyond the daily share-price moves, Abbott Laboratories remains a significant player in diagnostics and precision medicine, with past-year revenue cited at USD 40.11 billion across leading precision medicine companies, including Abbott, according to an industry ranking compiled by Market Growth Reports.

The same overview notes that Abbott has introduced an expanded suite of rapid molecular point-of-care diagnostic devices designed to integrate into outpatient oncology clinics, enabling immediate patient stratification before targeted therapy infusion, which illustrates how the company is positioned to capture demand for more individualized care pathways as of September 2, 2026.

Representative product: point-of-care molecular diagnostics

One representative product area for Abbott Laboratories is its rapid molecular point-of-care diagnostic platforms used to test patients in oncology settings and other high-acuity environments, where fast and accurate results can guide treatment decisions and help physicians determine which targeted therapies are appropriate in near real time.

Stock level and investor perspective

With Abbott Laboratories stock trading around USD 108.93 on the New York Stock Exchange as of September 2, 2026, according to Stake data, investors are watching whether the combination of large market capitalization at USD 190.97 billion and the 17.1 percent share-price decline over the past year will attract value-oriented interest or keep the stock in a consolidation phase.